Intracellular iron, essential for cancer cell proliferation and metabolism, is modified in cancer cells. Triple-negative breast cancers are metastatic cancers associated with a high recurrence rate, poor prognosis and lack of effective targeted therapies. We are investigating the potential of Deferiprone, a clinically approved intracellular iron chelator for non-cancer related diseases, to improve chemotherapeutic treatment response in triple-negative breast cancer by altering iron-dependent proliferation and metabolism. The effectiveness of Deferiprone to impair triple-negative breast cancer cell growth and affect cellular metabolism was evaluated by monitoring live cells, exposed to Deferiprone, in an MR-compatible cell bioreactor using multi-nuclear MRS.
This abstract and the presentation materials are available to members only; a login is required.